PREMIUM NEWS ARCHIVE
Article from: Blood Weekly
Article date: March 19, 2009
Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced that results from ongoing Phase II clinical trials of CougarEs investigational drug CB7630 (abiraterone acetate) were presented at the ASCO Genitourinary Cancers Symposium that is currently taking place in Orlando, Florida. The data were presented today in two poster presentations. These presentations are further detailed below: Abiraterone Acetate Plus Prednisone in Chemotherapy Naive Castration Resistant Prostate Cancer (CRPC) Patients Not Exposed to Ketoconazole: Results of ...
Read full article (with a Free Trial at HighBeam Research)